ROHTO Pharmaceutical Co.

Ōsaka, Japan

ROHTO Pharmaceutical Co.

Ōsaka, Japan

Time filter

Source Type

Patent
Sakai Chemical Industry Co. and Rohto Pharmaceutical Co. | Date: 2015-04-27

The inventors have investigated a fluorescent substance being safe and having a high color developing property, and it is one of objects of the present disclosure to obtain an inorganic red fluorescent substance consisting of an element which exerts no bad influence upon human bodies. A cosmetic containing inorganic particles consisting of a compound represented by a general formula: Ca_(x)Al_(y)O_((2x+3y+4z)/2):Mn^(4+)_(z ) wherein 0.1


Patent
Sakai Chemical Industry Co. and Rohto Pharmaceutical Co. | Date: 2017-03-08

The inventors have investigated a fluorescent substance being safe and having a high color developing property, and it is one of objects of the present disclosure to obtain an inorganic red fluorescent substance consisting of an element which exerts no bad influence upon human bodies. A cosmetic containing inorganic particles consisting of a compound represented by a general formula:Ca_(x)Al_(y)O_((2x+3y+4z)/2):Mn^(4+)_(z)wherein 0.1


Patent
ROHTO Pharmaceutical Co. | Date: 2015-06-09

An aqueous ophthalmic composition is provided comprising at least one component which is selected from the group consisting of a polysaccharide, a monosaccharide, at least one vitamin component selected from the group consisting of vitamin B12, vitamin B2, vitamin A and panthenol, at least one oil component selected from the group consisting of a plant oil, an animal oil and a mineral oil, at least one surfactant selected from the group consisting of polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol and polyoxyl stearate, an anti-allergic component, a preservative, a thickening component, a polyhydric alcohol, an anti-inflammatory component, an anti-bacterial agent and a cooling and/or refreshing agent; and (B) a buffering agent. When the composition is brought into contact with a polybutylene terephthalate-containing resin container, the container can be prevented from weight change, deterioration and wetting and can be improved in a liquid cutting property.


Patent
Rohto Pharmaceutical Co. | Date: 2015-06-30

An object of the present invention is to provide an external use composition having a novel composition that has a superior effect promoting collagen production and is able to suppress, prevent or improve wrinkles and sagging of the skin with aging. The present invention relates to an external use composition for anti-aging, comprising (A) a lipopeptide represented by the following formula (1), or a pharmaceutically acceptable salt thereof: (wherein, R^(1 )represents a saturated aliphatic group, or aliphatic group having a single unsaturated bond, having 9 to 19 carbon atoms, and m represents 0 or 1).


Patent
Rohto Pharmaceutical Co. | Date: 2015-12-09

An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.


Patent
Rohto Pharmaceutical Co. | Date: 2015-02-27

This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil and (B) sesame oil. According to the aqueous ophthalmic composition of the present invention, defoaming time is reduced, preservative efficacy is enhanced and photostability is improved.


Patent
Rohto Pharmaceutical Co. | Date: 2015-04-10

This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the average number of moles of added ethylene oxide is 2 to 12 and (B) terpenoid. According to the present invention, an aqueous ophthalmic composition having an improved foam disappearance speed can be obtained.


Patent
Rohto Pharmaceutical Co. | Date: 2015-02-04

Provided is a novel compound which has excellent ultraviolet-absorbing function (especially UVA absorbing function) and excellent hydrophilicity. A benzylidene azolidine derivative of the present invention or a salt thereof is characterized by being a benzylidene azolidine derivative represented by specif ic structural formula (I) or a salt thereof. (In structural formula (I), n represents an integer of 1-5; A^(1) represents O, S or N-A^(4); and each of A^(2), A^(3) and A^(4) independently represents a hydrogen atom, an alkyl group which may be substituted by a hydroxyl group and has 1-8 carbon atoms, or the like (provided that at least one of A^(2), A^(3) and A^(4) contains one or more hydroxyl groups). In this connection, when n is an integer of 2-5, the plurality of A^(3)O- moieties may be the same as or different from each other.)


Patent
Rohto Pharmaceutical Co. | Date: 2016-05-05

The present invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil, (B) polyethylene glycol monostearate, and (C) at least one member selected from the group consisting of sesame oil, castor oil, vitamin A, and chlorobutanol.


Patent
Rohto Pharmaceutical Co. | Date: 2016-01-27

An ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent has an advantage that the loss of the geranylgeranylacetone content during long-term storage is very little. This is because of reduced adsorption of geranylgeranylacetone to a wall of an ophthalmic container. The ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent also has an advantage that adsorption of geranylgeranylacetone to a contact lens is little. Further, the ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent hardly becomes white turbid even when stored at low temperature.

Loading ROHTO Pharmaceutical Co. collaborators
Loading ROHTO Pharmaceutical Co. collaborators